Serum Immunoglobulins and Risk of Infection: How Low Can You Go?

被引:116
作者
Furst, Daniel E. [1 ]
机构
[1] Univ Calif Los Angeles, Los Angeles, CA 90095 USA
关键词
immunoglobulins; IgG; IgA; IgM; infections; CHRONIC LYMPHOCYTIC-LEUKEMIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RECURRENT RESPIRATORY-INFECTIONS; COMMON VARIABLE IMMUNODEFICIENCY; INTRAVENOUS IMMUNOGLOBULIN; RHEUMATOID-ARTHRITIS; B-LYMPHOCYTE; REPLACEMENT THERAPY; EPILEPTIC PATIENTS; NEPHROTIC SYNDROME;
D O I
10.1016/j.semarthrit.2008.05.002
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objectives: To determine the relationship between the levels of serum immunoglobulin (Ig) levels and risk of infection. The following 2 main questions are addressed: (1) At what level do reduced serum concentrations of the different Ig species (focusing on IgA, IgG, and IgM) significantly increase the risk of infection above background and (2) For how long can Ig depletion be tolerated before an increased risk of infection becomes apparent. Methods: Information was gathered from a search of PubMed and relevant congress abstracts up to and including November 2007. Results: Sustained, very low levels of IgA, IgG, or IgM, as occur in primary immunodeficiency syndromes, are associated with significantly increased risks of infections, primarily respiratory tract infections of bacterial origin. Patients with IgG levels <100 mg/dL or IgM levels <20 mg/dL for prolonged periods have an increased risk of recurrent and sometimes life-threatening infectious episodes. Generally, IgA deficiency appears better tolerated. Replenishment of IgG in patients with hypogammaglobulinemia reduces the infection risk to background if IgG levels are maintained at approximately 500 mg/dL, although higher levels may be necessary in the presence of certain comorbidities. Transient depletion of IgG and/or IgM (or, less commonly, IgA) can occur in some patients following the administration of certain drugs, including anticonvulsants, corticosteroids, and rituximab. Available evidence suggests that such changes are not generally associated with an increased risk of infections. Conclusions: While prolonged, very low levels of IgG and/or IgM are associated with a heightened risk of infections, transient or less severe immunodeficiency appears to be tolerated in most subjects. (C) 2008 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 39:18-29
引用
收藏
页码:18 / 29
页数:12
相关论文
共 79 条
[1]
Hypogammaglobulinemia during antipsychotic therapy [J].
Abe, S ;
Suzuki, T ;
Hori, T ;
Baba, A ;
Shiraishi, H .
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 1998, 52 (01) :115-117
[2]
Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency [J].
Aghamohammadi, A ;
Farhoudi, A ;
Moin, M ;
Rezaei, N ;
Kouhi, A ;
Pourpak, Z ;
Yaseri, N ;
Movahedi, M ;
Gharagozlou, M ;
Zandieh, F ;
Yazadni, F ;
Arshi, S ;
MohammadZadeh, I ;
Ghazi, BM ;
Mahmoudi, M ;
Tahaei, S ;
Isaeian, A .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (07) :825-832
[3]
Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia [J].
Aghamohammadi, A ;
Moin, M ;
Farhoudi, A ;
Rezaei, N ;
Pourpak, Z ;
Movahedi, M ;
Gharagozlou, M ;
Nabavi, M ;
Shahrokhi, A .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2004, 40 (02) :113-118
[4]
Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection [J].
Alwadhi, RK ;
Mathew, JL ;
Rath, B .
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2004, 40 (1-2) :28-32
[5]
Primary immunodeficiency disorders: Antibody deficiency [J].
Ballow, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (04) :581-591
[6]
BASCOM R, 2006, IMMUNOGLOBULIN DEFIC
[7]
Bayrakci B, 2005, TURKISH J PEDIATR, V47, P239
[8]
BIRDSALL HH, 2004, ANTIBODIES
[9]
Population prevalence of diagnosed primary immunodeficiency diseases in the United States [J].
Boyle, J. M. ;
Buckley, R. H. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) :497-502
[10]
Immunoadsorption, current status and future developments [J].
Braun, N ;
Bosch, T .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) :2017-2038